Table 1.
Characteristics of TNBC and Non-TNBC Study Participants
| TNBC N=60 (16.7%) |
Non-TNBC N=299 (83.3%) |
p-value | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Demographic Characteristics | |||||
| Age | |||||
| <=50 | 23 | 38.3 | 106 | 35.5 | 0.671 |
| >50 | 37 | 61.7 | 193 | 64.6 | |
| Mean (SD) | 54.4 (12.0) | 54.9 (11.6) | 0.758 | ||
| Race | |||||
| White | 19 | 31.7 | 130 | 43.5 | 0.090 |
| Black | 41 | 68.3 | 169 | 56.5 | |
| Education | |||||
| No college education | 19 | 31.7 | 59 | 19.7 | 0.109 |
| Some college | 17 | 28.3 | 89 | 29.8 | |
| Bachelors and above | 24 | 40.0 | 151 | 50.5 | |
| Marital Status | |||||
| Married / Living as Married | 29 | 48.3 | 153 | 51.2 | 0.688 |
| CurrentlySingle | 31 | 51.7 | 146 | 48.8 | |
| Employment | |||||
| Full Time Employed | 21 | 36.8 | 106 | 37.9 | 0.885 |
| Other | 36 | 63.2 | 174 | 62.1 | |
| Clinical Characteristics | |||||
| ER Status | |||||
| Positive | 0 | 0.0 | 270 | 90.3 | <0.0001 |
| Negative | 60 | 100.0 | 29 | 9.7 | |
| PR Status | |||||
| Positive | 0 | 0.0 | 236 | 78.9 | <0.0001 |
| Negative | 60 | 100.0 | 63 | 21.1 | |
| Her2 Status | |||||
| Positive | 0 | 0.0 | 42 | 18.3 | <0.0001 |
| Negative | 60 | 100.0 | 188 | 81.7 | |
| Surgery | |||||
| Lumpectomy | 42 | 70.0 | 188 | 63.3 | 0.328 |
| Mastectomy | 18 | 30.0 | 109 | 36.7 | |
| Time from Diagnosis to Surgery (days) : Mean (SD) | 71.6 (102.3) | 61.9 (83.6) | 0.454 | ||
| Nodal Status | |||||
| Positive | 22 | 36.7 | 105 | 38.9 | 0.749 |
| Negative | 38 | 63.3 | 165 | 61.1 | |
| Tumor Size | |||||
| <2cm | 24 | 40.0 | 154 | 57.0 | 0.017 |
| ≥2cm | 36 | 60.0 | 116 | 43.0 | |
| Chemotherapy Use | |||||
| Yes | 36 | 60.0 | 105 | 35.1 | 0.0003 |
| No | 24 | 40.0 | 194 | 64.9 | |
| Time from Surgery to Chemotherapy (days) | |||||
| <60 days | 17 | 63.0 | 34 | 46.0 | 0.130 |
| ≥60 days | 10 | 37.0 | 40 | 54.1 | |
| Mean (SD) | 72.4 (78.0) | 73.1 (51.4) | 0.970 | ||
| Radiation Use | |||||
| Yes | 39 | 65.0 | 175 | 58.5 | 0.351 |
| No | 21 | 35.0 | 124 | 41.5 | |
| Chemotherapy Indicated ** | |||||
| Indicated | 60 | 100.0 | 127 | 46.5 | <0.0001 |
| Considered | 0 | 0.0 | 146 | 53.5 | |
| Comorbidities | |||||
| No comorbid disease | 17 | 28.3 | 108 | 36.1 | 0.248 |
| ≥1 comorbid diseases | 43 | 71.7 | 191 | 63.9 | |
| Diabetes | |||||
| Yes | 6 | 10.0 | 35 | 11.7 | 0.705 |
| No | 54 | 90.0 | 264 | 88.3 | |
| Hypertension | |||||
| Yes | 21 | 35.0 | 100 | 36.9 | 0.782 |
| No | 39 | 65.0 | 171 | 63.1 | |
| Body Mass Index (BMI) | |||||
| Not obese (<30 kg/m2) | 34 | 58.6 | 178 | 63.1 | 0.520 |
| Obese (≥30 kg/m2) | 24 | 41.4 | 104 | 36.9 | |
| Mean (SD) | 29.7 (6.6) | 28.8 (6.6) | 0.351 | ||
P-values are obtained from Chi square tests and t-tests.
Percentages add up to 100 along columns for the “total”, TNBC and Non-TNBC.
Abbreviations: NCI =National Cancer Institute; ER= Estrogen Receptor; PR=Progesterone Receptor; SD= Standard Deviation